Inhibition of platelet aggregation by a placental substance with prostacyclin-like activity

L. Myatt, M. G. Elder

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

THE demonstration that certain arteries and veins have the ability to generate from prostaglandin (PG) endoperoxides an unstable substance called prostacyclin (PGl2) (ref. 1), which will inhibit platelet aggregation2,3, should lead to a reappraisal of the homeostatic mechanisms preventing thrombosis. It has been suggested that the endothelium of these blood vessels contains an enzyme which is capable of converting PG endoperoxides from circulating platelets into an unstable substance, prostacyclin. This inhibits platelet aggregation and so prevents the initial step of thrombus formation within the vessel4. Damage to the endothelium of the vessel wall may prevent production of the enzyme PGI 2 synthetase, and the subsequent reduction in the local synthesis of prostacyclin could facilitate platelet aggregation in the area of damage. Maintenance of an adequate circulation within the placenta is critical to foetal well-being. This circulation is one both of low pressure and velocity and the presence of a substance which has a potent inhibitory effect on platelet aggregation would seem desirable for its maintenance. We demonstrate here the ability of normal placental tissue to generate a labile substance which has the ability to inhibit ADP-induced platelet aggregation. The properties exhibited by this substance are suggestive of it being PGI2.

Original languageEnglish (US)
Pages (from-to)159-160
Number of pages2
JournalNature
Volume268
Issue number5616
DOIs
StatePublished - 1977
Externally publishedYes

Fingerprint

Epoprostenol
Platelet Aggregation
Prostaglandin Endoperoxides
Endothelium
Thrombosis
Blood Platelets
Enzymes
Ligases
Adenosine Diphosphate
Placenta
Blood Vessels
Veins
Arteries
Maintenance
Pressure

ASJC Scopus subject areas

  • General

Cite this

Inhibition of platelet aggregation by a placental substance with prostacyclin-like activity. / Myatt, L.; Elder, M. G.

In: Nature, Vol. 268, No. 5616, 1977, p. 159-160.

Research output: Contribution to journalArticle

Myatt, L. ; Elder, M. G. / Inhibition of platelet aggregation by a placental substance with prostacyclin-like activity. In: Nature. 1977 ; Vol. 268, No. 5616. pp. 159-160.
@article{ed17f25411ac48759d18ff35f99797ae,
title = "Inhibition of platelet aggregation by a placental substance with prostacyclin-like activity",
abstract = "THE demonstration that certain arteries and veins have the ability to generate from prostaglandin (PG) endoperoxides an unstable substance called prostacyclin (PGl2) (ref. 1), which will inhibit platelet aggregation2,3, should lead to a reappraisal of the homeostatic mechanisms preventing thrombosis. It has been suggested that the endothelium of these blood vessels contains an enzyme which is capable of converting PG endoperoxides from circulating platelets into an unstable substance, prostacyclin. This inhibits platelet aggregation and so prevents the initial step of thrombus formation within the vessel4. Damage to the endothelium of the vessel wall may prevent production of the enzyme PGI 2 synthetase, and the subsequent reduction in the local synthesis of prostacyclin could facilitate platelet aggregation in the area of damage. Maintenance of an adequate circulation within the placenta is critical to foetal well-being. This circulation is one both of low pressure and velocity and the presence of a substance which has a potent inhibitory effect on platelet aggregation would seem desirable for its maintenance. We demonstrate here the ability of normal placental tissue to generate a labile substance which has the ability to inhibit ADP-induced platelet aggregation. The properties exhibited by this substance are suggestive of it being PGI2.",
author = "L. Myatt and Elder, {M. G.}",
year = "1977",
doi = "10.1038/268159a0",
language = "English (US)",
volume = "268",
pages = "159--160",
journal = "Nature",
issn = "0028-0836",
publisher = "Nature Publishing Group",
number = "5616",

}

TY - JOUR

T1 - Inhibition of platelet aggregation by a placental substance with prostacyclin-like activity

AU - Myatt, L.

AU - Elder, M. G.

PY - 1977

Y1 - 1977

N2 - THE demonstration that certain arteries and veins have the ability to generate from prostaglandin (PG) endoperoxides an unstable substance called prostacyclin (PGl2) (ref. 1), which will inhibit platelet aggregation2,3, should lead to a reappraisal of the homeostatic mechanisms preventing thrombosis. It has been suggested that the endothelium of these blood vessels contains an enzyme which is capable of converting PG endoperoxides from circulating platelets into an unstable substance, prostacyclin. This inhibits platelet aggregation and so prevents the initial step of thrombus formation within the vessel4. Damage to the endothelium of the vessel wall may prevent production of the enzyme PGI 2 synthetase, and the subsequent reduction in the local synthesis of prostacyclin could facilitate platelet aggregation in the area of damage. Maintenance of an adequate circulation within the placenta is critical to foetal well-being. This circulation is one both of low pressure and velocity and the presence of a substance which has a potent inhibitory effect on platelet aggregation would seem desirable for its maintenance. We demonstrate here the ability of normal placental tissue to generate a labile substance which has the ability to inhibit ADP-induced platelet aggregation. The properties exhibited by this substance are suggestive of it being PGI2.

AB - THE demonstration that certain arteries and veins have the ability to generate from prostaglandin (PG) endoperoxides an unstable substance called prostacyclin (PGl2) (ref. 1), which will inhibit platelet aggregation2,3, should lead to a reappraisal of the homeostatic mechanisms preventing thrombosis. It has been suggested that the endothelium of these blood vessels contains an enzyme which is capable of converting PG endoperoxides from circulating platelets into an unstable substance, prostacyclin. This inhibits platelet aggregation and so prevents the initial step of thrombus formation within the vessel4. Damage to the endothelium of the vessel wall may prevent production of the enzyme PGI 2 synthetase, and the subsequent reduction in the local synthesis of prostacyclin could facilitate platelet aggregation in the area of damage. Maintenance of an adequate circulation within the placenta is critical to foetal well-being. This circulation is one both of low pressure and velocity and the presence of a substance which has a potent inhibitory effect on platelet aggregation would seem desirable for its maintenance. We demonstrate here the ability of normal placental tissue to generate a labile substance which has the ability to inhibit ADP-induced platelet aggregation. The properties exhibited by this substance are suggestive of it being PGI2.

UR - http://www.scopus.com/inward/record.url?scp=0017722718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017722718&partnerID=8YFLogxK

U2 - 10.1038/268159a0

DO - 10.1038/268159a0

M3 - Article

VL - 268

SP - 159

EP - 160

JO - Nature

JF - Nature

SN - 0028-0836

IS - 5616

ER -